NOVARTIS IN A MOUSE HOLE WITH ITS BTK INHIBITOR
April 10, 2026
But meanwhile, Novartis, with its molecule remibrutinib, or Rhapsido, another BTK inhibitor, could well be the big winner of this race.
Bruton tyrosine kinase inhibitors developed by Roche would apparently be far more effective than those from Sanofi. Indeed, Roche's fenebrutinib met its primary endpoint in a second Phase III study for the treatment of relapsing multiple sclerosis (RMS). These latest data give the Swiss giant the opportunity to submit its compound to the FDA gauntlet, something that is still denied to Sanofi. Roche's drug candidate reportedly induced a 59% reduction in the annualized relapse rate (ARR) versus Aubagio in the first Phase III in PPMS. Then, in the second Phase III in RMS, it produced a reduction of the same order once again vers...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.
Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.
RELATED ARTICLES
UN JOUR NOUVEAU POUR SERVIER
Finalement, la Fondation internationale de recherche Servier franchit le pas et s’est offert Day One Biopharmaceuticals pour 2,17 Mds $. Avec applicat
PSCC: TAILORED SUPPORT FOR INNOVATORS IN ONCOLOGY
Located south of Paris, the PSCC aims to become a European hub of excellence in oncology by supporting innovative research projects and transforming t
WITH ALBERT'S GREETINGS
In France, we would have mentioned the end of the honeymoon period, but in the United States, given the current situation, the metaphor of the lid ab